Prognostic factors in advanced pharyngeal and oral cavity cancer; significance of multimodality imaging in terms of 7th edition of TNM
© Gődény; licensee BioMed Central Ltd. 2014
Received: 27 March 2014
Accepted: 27 March 2014
Published: 28 April 2014
As with most cancers the prognosis in pharyngeal and oral cavity cancer largely depends on tumour stage. Physical examination, including endoscopy should be combined with technical radiologic imaging to record the precise extent of tumour. The TNM staging system of the head and neck region is, in fact, an anatomic staging system that describes the anatomic extent of the primary tumour as well as the involvement of regional lymph nodes and distant metastases. Modifications in the TNM staging system should consider not only the expert opinions and published reports in the literature but the technical advances in technology for improved assessment of tumour extent and the shifting paradigms in therapeutic strategies. “T” stage of the tumour is defined by its size, the depth of the invasion and the involvement of vital structures. In the 7th edition of TNM classification, for stage T4 tumors (larger than 4 cm), subcategories a and b were introduced to indicate the involvement of vital structures and their suitability for surgical resection (except for nasopharynx cancer). Nodal metastasis is the most important predictor of outcome for squamous cell cancer of the head and neck.
Better and more reliable methods of pretreatment tumour assessment are therefore crucial to ensure that the clinical assessment of tumor approximates its actual pathologic extent.
CT and MRI are both useful for assessing extensions of pharyngeal- and oral cavity cancer in advanced stage. MRI is superior in visualizing most primary tumour sites.
Hungary is first in pharyngeal- and oral cavity cancer (Ph-OC-CA) mortality in Europe in either sex. The male Ph-OC-Ca mortality is fourth in all cancer mortality in Hungary.
The majority of mucosal cancers in this country are squamous cell carcinomas (SCCA). Like in most cancers, the prognosis mainly depends on the stage of the tumour.
Head and neck (HN) is a difficult region, both its anatomy and pathology is very complex, various connection points may exist between the sites that determines the extension of disease.
Evaluation of Clinical Stage is based primarily on inspection, and palpation of the sites and on indirect and direct endoscopy. Neurologic evaluation of all cranial nerves is also required in advanced stage. Complete endoscopy, usually under general anesthesia, is performed after completion of other staging studies.
Imaging plays a crucial role in defining the extension of cancer and in therapy planning, as well. The accuracy of image evaluation depends very much on the experience and competence of radiologists. They have to be familiar with the anatomy and pathology of this region and the clinical details of the patient as well, in order to determine the most accurate stage of tumour.
Basic aspects in the management of advanced head and neck cancer
There are new aspects in management of advanced Ph-OC-CA. One of the major endpoints of interest in management is to improve the quality of life, to preserve organ function without compromising survival. Chemotherapy and radiotherapy are considered as standards in treatment, but not all patients are suitable for organ preservation therapy. Patients with no response to standard therapy have to undergo salvage surgery. Criteria of inoperability have changed, consequently at present more extented resections and reconstructions are performed . Tthe 3D-conformal-, intensity modulated radiotherapy (IMRT), for its better technical capacity, has resulted in a reduction of the dose delivered to normal tissues because of focusing more precisely on the target volumes. This means that more accurate assessment of tumour borders and tumour volume as well as of biological target volume is required in therapy planning .
Changes in treatment strategy of advanced HN cancer, necessitate more accurate radiological evaluation, knowledge of more tumour characteristics and prognostic factors.
It is crucial to ensure that the radiological diagnosis of the tumour status is concordant with the actual pathological status.
Prognostic Factors affect patient’s survival and modify the therapeutic strategies. Tumour-related prognostic factors are: the primary tumour (T) size and its depth of invasion, the Grade of tumor, and the presence or absence of vascular invasion, − although the latter is particularly not included in the staging of HN tumours, but it should be noted when present [3, 4]. The presence of metastatic lymph nodes (N), and their size, number, and position (level), as well as signs of extracapsular tumour spread (ECS) are important prognostic factors . Mediastinal nodal spread is counted as distant metastasis, except those of level VII. The incidence of distant metastatic disease increases with rising tumour stage. Risk of distant metastasis is more dependent on “N” than on “T” status. As a rule, in Ph-OC-CA most metastases (M) develop in the lungs and the bones (rarely in the liver and brain). The data in the literature suggest that the rate of lung metastasis in newly diagnosed head and neck SCCA ranges from 16% to 19% using CT of the thorax [6, 7]. Nasopharyngeal and adenoid cystic carcinomas (ACCA) have an increased risk of developing distant metastases.
In addition to the importance of the TNM factors, the overall health of these patients clearly influences the outcome. In some ongoing studies authors attempt to use both tumour and non-tumour related factors for the better evaluation of prognosis [4, 8].
Principle of the new, 7th TNM cancer staging
Numerous factors affect patient’s survival, including the histologic diagnosis, cellular differentiation of the tumour (grade), location and size, local extension, and the status of regional lymph nodes as well as the presence of distant metastases . The importance of accurate mapping of the tumour before determining therapy has always been recognized by the Collaborative TNM System of the American Joint Committee on Cancer (AJCC) and the International Union for Cancer Control (UICC). The TNM system is periodically revised in response to newly acquired clinical data reflecting the new therapeutic strategies, improving understanding of cancer biology, and factors affecting prognosis. The revision cycle for TNM staging is 6–8 years. This provides sufficient time for the implementation of changes in clinical guidelines and cancer registry and for the discussion of data supporing changes in staging [3, 4].
The 7”th TNM Revision is valid from 01, January, 2010 onwards. The anatomic extent of the disease remained the decisive factor in establishing prognosis in Ph-OC-CA.
The classification involves only four dominant clinical variables: tumour size, local extension of the tumour, nodal metastasis, and distant metastasis. Histologic grade, patient age and tumor site are important additional factors that should be recorded for future analysis and potential inclusion in the staging system.
ESMO Guidelines/2010 approved by the ESMO Guidelines Working Group, accepted the new therapy-guided 7th TNM strategies . The guideline approved T4 tumors subdivision (except for nasopharyngeal cancer) into T4a: moderately advanced lesions and T4b: very advanced lesions with local extension. Clinical prognostic cancer stage IV was divided into: A, B, C subcategories. Stage IVA: moderately advanced (surgically resectable, suitable for salvage operation. Stage IVB: very advanced, “unresectable” are generally acknowledged as indicative of extension of tumor to vital anatomic structures, where surgical resection is either technically not feasible or not recommended however, it is potentially treatable with radio-chemotherapy. Stage IVC: stands for metastatic disease, only for palliative treatment: chemotherapy, radiotherapy.
Role of imaging in clinical staging
Clinical staging, based on the best possible imaging technique, estimates the extent of disease before the first treatment. In the last ESMO Guidelines/2010 the diagnostic modalities in clinical staging were determined: physical examination, CT, MRI, HN-endoscopy and chest X-ray. According to the new EHNS-ESMO-ESTRO Clinical Practice: Guidlines for diagnosis, treatment and follow-up of the squamous cell carcinoma of the head and neck: MRI is considered the preferable staging procedure for every tumour subsite of the HN - except laryngeal and hypopharyngeal cancer . MRI offers the best soft tissue differentiation, best evaluation of tumour borders, tumour extension, the most optimal evaluation of intracranial, perineural tumour spread, and also enables the radiologist to analyse vascularity. CT imaging with axial and coronal thin section technique using contrast agent is an excellant alternative diagnostic tool in Ph-OC-CA. In many institutions, CT is the preferred imaging method for the routine evaluation of head and neck cancer. In most cases a dedicated CT study will answer most questions of the referring clinician. CT is superior in the routine work to MRI: wide spread use, easy performance, standard reproducibility, relatively low cost, short examination time, resulting less motion artefact, superior information of cortical bone and bone lamellas without marrow space. CT can be regarded as the’workhorse’ of head and neck cancer imaging .
3 T MR scanners can provide higher resolution images for better tissue definition and can also benefit from MR-spectroscopic imaging (MRSI) applications. MRI is a true cancer imaging biomarker. It may provide more physiologic and functional qualitative and quantitative data using dynamic contrast enhanced MRI (DCE-MRI), diffusion weighted MRI (DW-MRI) and can further improve the assessment of target volumes and can provide an opportunity to nominate the biological target volume and the potential to determine treatment response. The diagnostic accuracy of DWI complements anatomical MR imaging for staging neck lymph nodes in head and neck cancer (HNCA) [11–14].
The better estimation of target volumes with CT and MRI may permit treatment individualization . The superior characterization of soft tissues and better visualization of tumour extent may be benefecial for radiotherapy planning because a more precise delineation of margins for the organ sparing strategies with boosting and dose escalation is feasible. The value of DW-MRI in radiotherapy planning is also under investigation. DW-MRI is able to characterize tissues and generate image contrast based on differences in histological micro-structures non-invasively, and based on water movement, improves the target delineation [11, 13–16].
These techniques may also be combined with PET/CT to further increase diagnostic sensitivity and specificity. The role of FDG-PET/CT in staging is under investigation, it has a lower specificity than sensitivity and is more useful for staging distant metastases and synchronous tumour than lymphnode metastasis [1, 17, 18].
The need for extensive imaging to identify metastatic disease depends on the consideration of tumour site, stage of disease and histology. In advanced Ph-OC-CA a careful multimodality imaging search is mandatory also for other primary tumours of the upper aerodigestive tract and because of the higher incidence of multiple independent primary tumours occuring simultaneously .
US has been widely used in the assesment of cervical lymph node status, but it is not reliable for the deep nodes. US guided Fine-needle aspiration biopsy (USgFNAB) may confirm the tumour, its histopathologic nature, but it cannot rule out the presence of tumor .
Key points in the evaluation of different Ph-OC-CA
Oral cavity cancers (OCCA)
The oral cavity is divided into the following specific sites:
Mucosal Lip (40% of OCCs), Buccal Mucosa, Lower Alveolar Ridge, Upper Alveolar Ridge, Retromolar Gingiva (Retromolar Trigone), Floor of the Mouth (15% of OCCs).
Hard Palate (5% of OCCs), Anterior two-thirds of the tongue (Oral Tongue, 20% of OCCs) The tongue is most commonly involved in the middle, and in the posterior third, mainly on the lateral, and lower surface. Human papilloma virus (HPV) DNA is prevalent in about 50% of oral cancer cases . In OCCA submucosal spread is common. Tumours of each anatomic site have their own predictable patterns of regional spread . The region of the retromolar trigone has important connection to the neighbouring cervical spaces, along the mandible to the pterygomandibular space and on this way to the parapharyngeal space till the skull base. Perineural spread may also occur .
The tongue is richly supplied with lymphatics, nearly half of patients have N metastases, 30%o of them are bilateral at the initial clinical presentation. Many of these nodes are clinically silent, detected only by imaging. Tumour thickness is also a prognostic factor that predicts subclinical nodal metastasis, local recurrence and patient survival .
Key points in the’T’evaluation in advanced stages
T3 – TU more than 4 cm in greatest dimension
T4a – Moderately advanced local disease : tumour invades the cortical bone, mandible, inferior alveolar nerve, deep/extrinsic muscle of tongue (genioglossus, hyoglossus, palatoglossus, styloglossus), maxillary sinus, skin of face
T4b - Very advanced local disease: tumour invades the pterygoid plates, or skull base and/or encases internal carotid artery
Note: Superficial erosion alone of bone/tooth socket by gingival primary is not sufficient to classify T4. tumour .
Nasopharyngeal cancer (NPhCA)
The primary tumour may be clinically occult and commonly present with neck nodal disease
Nodes may be also clinically silent, and detectable by MRI/CT. MR provides better delineation of RP nodes from an adjacent primary tumour. CT is rarely used to look at bone invasion if MRI is available. In the vast majority of the cases the management of NPhCA is confined to radiotherapy.
Key points in the’T’ evaluation in advanced stages
T3 – tumour invades bony structures of skull base and/or paranasal sinuses
T4 – tumour with intracranial extension and/or involvement of cranial nerves, hypopharynx, orbit, extension to the infratemporal fossa/masticator space
Oropharyngeal cancer (OPhCA)
The OPh includes the following specific sites:
The base of the tongue, the inferior (aterior) surface of the soft palate and the uvula, the anterior and posterior tonsillar pillars, the glossotonsillar sulci, the pharyngeal tonsils, and the lateral and posterior pharyngeal walls.
The human papillomavirus (HPV) status of a tumour is a strong and independent prognostic factor for survival in patients with cancers of the oropharynx- and oral cavity CA. Studies demonstrated that high HPV prevalence has been consistently demonstrated in OCCA/OPhCA compared to a lower prevalence in other HN-SCCAs. HPV positive tumours were observed in younger, lighter alcohol-consuming patients with a better overall and disease specific survival .
Key points in the’T’ evaluation in advanced stages
T3 – tumour >4 cm/extension to lingual surface of epiglottis
T4a – Moderately advanced local disease: tumour invades: larynx, extrinsic muscle of tongue, musculus pterygoideus medialis, hard palate, mandible
T4b - Very advanced local disease: tumour invades: musculus pterygoideus lateralis, pterygoid plates, NPh, skull base, prevertabral fascia, encases the carotid artery
Mucosal extension to lingual surface of epiglottis from primary tumours of the base of tongue and vallecula does not constitute invasion of larynx .
Hypopharyngeal cancer (HPhCA)
Bilateral lymphatic drainage is common. HPhCA spreads to adjacent parapharyngeal, jugular, paratracheal nodes: Levels: II, III, IV, VI and VII.
Key points in the’T’ evaluation in advanced stages
T3 – tumour more than 4 cm in greatest dimension, or with fixation of hemilarynx, or extension to esophagus
T4a – Moderately advanced local disease, tumour invades: thyroid-/cricoid cartilage, hyoid bone, thyroid gland, or central compartment soft tissue (central compartment soft tissue includes prelaryngeal strap muscles and subcutaneous fat)
T4b – Very advanced local disease, tumour invades retropharyngeal/prevertebral fascia, encases carotid artery, or involves mediastinal structures
Key points in the evaluation of the neck lymphnode status
The presence of neck adenopathies influences patient management, and largely determines the chance for locoregional control and the risk for distant metastasis. The risk of N metastasis is generally related to the depth of infiltration of the tumour.
Nodal disease can be treated either surgically, by performing a neck dissection, or by chemo-radiotherapy. Occurrence of N metastasis decreases the overall survival to its half . Tumours of each anatomic site have their own regional lymphatic spread and different metastatic potential. The lip-, hard palate-, alveolar ridge-, glottic, sinonasal cancers have low metastatic potential, but the other oral-, nasopharyngeal, meso-, hypopharyngeal, supraglottic cancers are in high risk metastatic group . In the high risk groups cancers spread primarily to the first lymphatic filter and to the lower level nodes, occasionally spread directly to the lower nodes. To facilitate communication, radiologists should be familiar with the anatomical distribution of cervical nodes (Figure 9) used by surgeon as well as pathologists .
Nasopharyngeal cancer: commonly spreads to retropharyngeal, upper jugular (Level II) and spinal accessory (Level V) nodes, often bilaterally. NPhCA with retropharyngeal node involvement is N1 stage - independent of laterality and without cervical node involvement (it is new in the 7th TNM)
Oral cavity cancer: commonly spreads to submental, submandibular (Level I), internal jogular (Level II) nodes.
Oropharyngeal cancer: involves upper and mid-jugular nodes (Level II, III) and (less commonly) submental/submandibular nodes (Level I)
Hypopharyngeal cancer: commonly spreads to adjacent parapharyngeal, paratracheal (Level VI), and mid- and lower jugular nodes (Level III, IV). Bilateral lymphatic drainage is common.
The cervical lymphnode classification for metastasis is uniform for all sites, except thyroid, nasopharynx, and skin. Node size, number and location are prognostic factors. Masses ≥ 3 cm are rarely single lymphnodes, but rather fusion of metastatic nodes.
N1: single N ≤ 3 cm,
N2a: single N ipsilateral > 3 cm ≤ 6 cm,
N2b: multiple ipsilateral ≤ 6 cm,
N2c: bilateral or contralateral N ≤ 6 cm,
N3: > 6 cm.
(The lymphnode size should be measured in greatest dimension.)
Midline N are considered ipsilateral N. The closer to the midline the tumour, the greater the risk of bilateral N metastasis is. Mediastinal N metastases are distant metastases, but superior mediastinal N are considered regional N (level VII) [3, 4].
Role of imaging to determine N status
Cervical lymphadenopathy is one of the most important key points of Ph-OC-CA. The sensivity (Sv) and specificity (Sp) of palpation for neck N metastasis are in the range of 60%-70% . Clinical evaluation of neck lymph nodes is not very precise, subclinical adenopathies may be detected by imaging studies . With US more nodes can be inspected than with the clinical examinations, but CT/MR/PET-CT are more accurate than US. Particular attention should be paid to clinically inaccessible nodal sites such as the retropharyngeal and paratracheal lymph nodes.
The radiological criteria of metastasis are based not only on increased N size (>1 cm), and round shape but rather on the presence of tumour colliquation, and tumour extension beyond the margin of the node. In the size criterion, the minimal axial diameter is more decisive than the other diameters . The inhomogeneous nodal structure, the signs of central necrosis, and the signs of the extranodal tumour spread, the spiculated margins, involvement of internodal fat, and loss of normal oval-round nodal shape distinctly appear on both CT and MRI and are typical signs for metastatic nodes. Both CT and MRI have accuracy (Acc) of 73%-80% to detect ENS [18, 29–31].
US is superior to palpation and has been widely used in the assesment of cervical lymphnode status, but it is not reliable for deep nodes (e.g., retropharyngeal nodes) because of its limited penetration into deeper layers. In addition, US is highly dependent on the experience of the operator. US is relatively cheap and capable of guiding tissue sampling. The USgFNAC has very high Sp, approaching 98-100% with a Sv of 73-80% , but this method is time consuming, and operator dependent [10, 19].
A meta-analysis comparing CT with physical examination (PE) yielded the following results: Sv, 83% (CT) vs 74% (PE); Sp 83% (CT) vs 81% (PE); and Acc, 83% (CT) vs 77% (PE). Overall, PE identified 75% of patologic cervical adenopathies. This detection rate increased to 91% with addition of CT [10, 32].
According to another analysis, the Acc of CT and MR in staging N involvement is almost similar (73-80%) . The advantage of these techniques is the standard, comprehensive evaluation of the entire head and neck region, also allowing detection of retropharangeal adenopathies [19, 28–30].
A tumour encircling the vessel over 270° on CT or MRI, or a tumour that is immobile from the vessel using sonopalpation, confirms the involvement of the vessel wall and is often non-resecable. With real time US can be helpful to detect carotid wall invasion [33, 34].
MR-lymphography for N staging, using superparamagnetic iron oxid particles as contrast agents, may increase accuracy, Sv of 86% and Sp of 100% for metastatic nodes, but micrometastases may be missed also with this method . (Disadvantage: MR-lymphangiographic agents are not commercially available at present)
Sentinel node biopsy is widely accepted as the standard practice in the management of breast cancer, cutaneous malignant melanoma and the procedure was also under investigation in HN-SCCA but with less accuracy than in the above mentioned tumours [36–38].
PET-CT can map functional and metabolic activity but less accurately can identify tumour in normal sized lymph nodes. Also the false negative necrotic nodes are potential pitfalls in the analysis of PET-CT. FDG-PET/CT has a lower specificity than sensitivity and more useful for detecting distant metastases and synchronous tumour than lymphnode metastasis [1, 17, 18].
None of the currently available imaging methods, including FDG-PET/CT, are reliable to detect small tumour deposits within non-enlarged lymph nodes, or differentiate reactively enlarged lymph nodes from metastatic lymphadenopathy. Patients with stage N0 still undergo elective nodal resection for diagnostic staging and 20-25% of the patients have metastatic nodes in pathology .
Accurate and reliable stratification of Ph-OC-CAs for the prediction of outcomes has been challenging, mainly because of the numerous anatomic sites and subsites from which tumours can arise and the diversity of histologic types of tumours in these locations.
Accuracy of pretreatment staging has become more critical after the introduction of “organ preservation” protocols, since non-surgical therapy and the very extended, more invasive salvage surgery have become widely accepted treatment possibilities.
“T” stage of the tumour is defined by its size, the depth of the invasion and the involvement of vital structures. Tumours that invade the prevertebral fascia, skull base, cranial nerves or encase the carotid or mediastinal great vessels are not resecable, are qualified as Stage T4b, according to the latest TNM classification.
In most cases treatment outcome is strongly influenced by the presence or absence of cervical nodal metastasis. Nodal necrosis and extracapsular spread indicates metastatic disease, irrespectively of nodal size.
Imaging plays an important role in clinical evaluation of head and neck lesions. A particular advantage of cross-sectional imaging is the ability to detect deep tumor extension or the presence or absence of metastases that cannot be judged by clinical examination. “Stage migration” occurs when patients are assigned to different clinical stages because of differences in the accuracy of the clinical examinations and imaging staging methods. Compared with conventional clinical examination, MRI and CT render a more precise assessment of tumour possible that may lead to the classification of the tumour into a higher clinical stage.
CT/MR are also mandatory in selecting patients for a favourable group for radiotherapy by providing an estimate of tumour borders and volume.
The radiologist’s task is to determine the site, extension and volume of the disease, to differentiate tumour from inflammation. Imaging can help oncologists, surgeons, radiotherapeutists better determine the location of tumours, confirm or exclude suspected diseases, avoid the complications, evaluate the clinical key points, and also detect the endoscopic ‘blind spots’ in clinically occult cases.
The accuracy of image evaluation depends highly on the experience and competence of radiologists. The radiologist plays an indisputable role in the Ph-OC-CA multidisciplinary team and has to be strongly committed to the management of patients.
To my colleagues in the Hungarian National Institute of Oncology.
- Grégorie V, Lefebvre J, Licitra L, Felip E: Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice: Guidlines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(7):184–86.View ArticleGoogle Scholar
- Lemort M, Canizares AC, Kampouridis S: Advances in imaging head and neck tumours. Curr Opin Oncol 2006, 18(3):234–239. 10.1097/01.cco.0000219251.15041.b1PubMedView ArticleGoogle Scholar
- Sobin LH, Gospodarowicz MK, Wittekind CH: TNM Classification of Malignant Tumours. 7th edition. Hoboken NJ: Willey-Blackwell; 2009.Google Scholar
- American Joint Committee on Cancer: AJCC Cancer Staging Handbook. 7th edition. New York: Springer; 2010.View ArticleGoogle Scholar
- Nakamura T, Sumi M: Nodal imaging in the neck: recent advances in US, CT and MR imaging of metastatic nodes. Eur Radiol 2007, 17: 1235–41. 10.1007/s00330-006-0490-0PubMedView ArticleGoogle Scholar
- De Bree R, Deurloo EE, Snow GB, Leemans CR: Screening for distant metastases in patients with head and neck cancer. Laryngoscope 2000, 110: 397–401. 10.1097/00005537-200003000-00012PubMedView ArticleGoogle Scholar
- Loh KS, Brown DH, Baker JT, Gilbert RW, Gullane PJ, Irish JC: A rational approach to pulmonary sreening in newly diagnosed head and neck cancer. Head Neck 2005, 27: 990–994. 10.1002/hed.20261PubMedView ArticleGoogle Scholar
- Takes RP, Rinaldo A, Silver CE, Piccirillo JF, Haigentz M Jr, Suárez C, Van der Poorten V, Hermans R, Rodrigo JP, Devaney KO, Ferlito A: Future of the TNM classification and staging system in head and neck cancer. Head Neck 2010, 32(12):1693–711. 10.1002/hed.21361PubMedView ArticleGoogle Scholar
- Chong VF: Tumour volume measurement in head and neck cancer. Cancer Imaging 2007, 7: 47–49. 10.1102/1470-7330.2007.9002View ArticleGoogle Scholar
- Hermans R: Head and Neck Cancer Imaging. 2nd edition. Berlin: Springer; 2012.View ArticleGoogle Scholar
- Hermans R, Vandecaveye V: Diffusion-weighted MRI in head and neck cancer. Cancer Imaging 2007, 7: 126–127. 10.1102/1470-7330.2007.0018PubMed CentralPubMedView ArticleGoogle Scholar
- Vandecaveye V, De Keyzer F, Dirix P, Lambrecht M, Nuyts S, Hermans R, Lambrecht M, Dirix P: Applications of diffusion-weighted magnetic resonance imaging in head and neck squamous cell carcinoma. Neuroradiology 2010, 52(9):773–84. 10.1007/s00234-010-0743-0PubMedView ArticleGoogle Scholar
- Sumi M, Sakihama N, Sumi T, Morikawa M, Uetani M, Kabasawa H, Shigeno K, Hayashi K, Takahashi H, Nakamura T: Discrimination of metastatic cervical lymph nodes with diffusion-weighted MR imaging in patients with head and neck cancer. AJNR Am J Neuroradiol 2003, 24: 1627–1634.PubMedGoogle Scholar
- Vandecaveye V, De Keyzer F, Vander Poorten V, Dirix P, Verbeken E, Nuyts S, Hermans R: Head and neck squamous cell carcinoma: value of diffusion-weighted MR imaging for nodal staging. Radiology 2009, 251: 134–46. 10.1148/radiol.2511080128PubMedView ArticleGoogle Scholar
- Nuyts S: Defining the tagret for radiotherapy of head and neck cancer. Cancer Imaging 2007, 7: 50–55. 10.1102/1470-7330.2007.9009View ArticleGoogle Scholar
- Razek AA, Soliman NY, Elkhamary S, Alsharaway MK, Tawfik A: Role of diffusion-weighted MR imaging in cervical lymphadenopathy. Eur Radiol 2006, 16: 1468–77. 10.1007/s00330-005-0133-xPubMedView ArticleGoogle Scholar
- Rankin SC: PET in face and neck tumours. Cancer Imaging 2006, 6: 105–11.View ArticleGoogle Scholar
- King AD: Multimodality imaging of head and neck cancer. Cancer Imaging 2007, 7: 37–46. 10.1102/1470-7330.2007.9013View ArticleGoogle Scholar
- Takes RP, Righi P, Meeuwis CA, Manni JJ, Knegt P, Marres HA, Spoelstra HA, de Boer MF, van der Mey AG, Bruaset I, Ball V, Weisberger E, Radpour S, Kruyt RH, Joosten FB, Laméris JS, van Oostayen JA, Kopecky K, Caldemeyer K, Henzen-Logmans SC, Wiersma-van Tilburg JM, Bosman FT, van Krieken JH, Hermans J, de Jong RJ B: The value of ultrasound-guided fine-needle aspiration biopsy compared to computed tomography in the detection of regional metastases in the clinically negative neck. Int J Radiat Oncol Biol Phys 1998, 40: 1027–32. 10.1016/S0360-3016(97)00953-XPubMedView ArticleGoogle Scholar
- Tshering Vogel DW, Zbaeren P, Thoeny HC: Cancer of the oral cavity and oropharynx. Cancer Imaging 2010, 10: 62–72.PubMedView ArticleGoogle Scholar
- Chong V: Oral cavity cancer. Cancer Imaging 2005, 5: S49-S52. 10.1102/1470-7330.2005.0029PubMed CentralPubMedView ArticleGoogle Scholar
- Lam P, Au-Yeung KM, Cheng PW, Wei WI, Po-Wing YA, Trendell-Smith N, Li JHC, Li R: Correlating MRI and histologic tumor thickness in the assessment of oral tongue cancer. AJR Am J Roentgenol 2004, 182: 803–808. 10.2214/ajr.182.3.1820803PubMedView ArticleGoogle Scholar
- Chong VF, Ong CK: Nasopharyngeal carcinoma. Eur J Radiol 2008, 66: 437–47. doi:10.1016/ejrad.2008.03.029. PMid:18485650 10.1016/j.ejrad.2008.03.029PubMedView ArticleGoogle Scholar
- Ringström E, Peters E, Hasegawa M, Posner M, Liu M, Kelsey KT: Human papillomavirus type 6 and squamous cell carcinoma of the head and neck. Clin Cancer Res 2002, 8(10):3087–92.Google Scholar
- Hermans R: Squamous Cell Cancer of the Neck. Cambridge: Cambridge University Press; 2008.View ArticleGoogle Scholar
- Hsu WC, Loevner LA, Karpati R, Ahmed T, Mong A, Battineni ML, Yousem DM, Montone KT, Weinstein GS, Weber RS, Chalian AA: Accuracy of magnetic resonance imaging in predicting absence of fixation of head and neck cancer to the prevertebral space. Head Neck 2005, 27(2):95–100. 10.1002/hed.20128PubMedView ArticleGoogle Scholar
- Hermans R: Staging of laryngeal and hypopharyngeal cancer: value of imaging studies. Cancer Imaging 2008, 8: 94–107. 10.1102/1470-7330.2008.9016View ArticleGoogle Scholar
- Som P, Curtin HD: Head and Neck Imaging. Mostby: Imaging-Based Neck Node Level System; 2003:1876–1880.Google Scholar
- Van den Brekel MWM, Castelijns AJ: What the clinician wants to know: surgical perspective and ultrasound for lymph node imaging of the neck. Cancer Imaging 2005, 5(Spec No A):41–49.View ArticleGoogle Scholar
- Castelijns AJ, Van den Brekel MWM: Neck Nodal Disease. Head and Neck Cancer Imaging Medical Radiology. Berlin Heidelberg: Springer; 2006:293–309.View ArticleGoogle Scholar
- King AD, Tse GMK, Yuen EHY, To EWH, Vlantis AC, Zee B, Chan ABW, Hasselt AC, Ahuja AT: Comparison of CT and MR imaging for the detection of extranodal neoplastic spread in metastatic neck nodes. Eur J Radiol 2004, 52: 264–270. 10.1016/j.ejrad.2004.03.004PubMedView ArticleGoogle Scholar
- Merritt RM, Williams MF, James TH, Porubsky ES: Detection of cervical metastasis. A meta-analysis comparing computed tomography with physical examination. Arch Otolaryngol Head Neck Surg 1997, 123: 149–152. 10.1001/archotol.1997.01900020027004PubMedView ArticleGoogle Scholar
- De Bondt RBJ, Nelemans PJ, Hofman PA, Casselman JW, Kremer B, van Engelshoven JM, Beets-Tan RG: Detection of lymph node metastases in head and neck cancer: a meta-analysis comparing US, USgFNAC, CT and MR imaging. Eur J Radiol 2007, 64: 266–272. 10.1016/j.ejrad.2007.02.037PubMedView ArticleGoogle Scholar
- Gritzmann N, Grasl MC, Helmer M, Steiner E: Invasion of the carotid artery and jugular vein by lymph node metastases: detection with sonography. AJR 1990, 154: 411–4. 10.2214/ajr.154.2.2105036PubMedView ArticleGoogle Scholar
- Baghi M, Mack MG, Hambek M, Rieger J, Vogl T, Gstoettner W, Knecht R: The efficacy of MRI with ultrasmall superparamagnetic iron oxide particles (USPIO) in head and neck cancers. Anticancer Res 2005, 25(5):3665–70.PubMedGoogle Scholar
- Nason RW, Torchia MG, Morales CM, Thliveris J: Dynamic MR lymphangiography and carbon dye for sentinel lymph node detection: a solution for sentinel lymph node biopsy in mucosal head and neck cancer. Head Neck 2005, 27(4):333–8. 10.1002/hed.20173PubMedView ArticleGoogle Scholar
- Kontio R, Leivo I, Leppanen E, Atula T: Sentinel lymph node biopsy in oral cavity squamous cell carcinoma without clinically evident metastasis. Head Neck 2004, 26(1):16–21. 10.1002/hed.10355PubMedView ArticleGoogle Scholar
- Werner JA, Dunne AA, Ramaswamy A, Dalchow C, Behr T, Moll R, Folz BJ, Davis RK: The sentinel node concept in head and neck cancer: solution for the controversies in the N0 neck? Head Neck 2004, 26(7):603–11. 10.1002/hed.20062PubMedView ArticleGoogle Scholar
- King AD, Ahuja AT, Yeung DK, Fong DK, Lee YY, Lei KI, Tse GM: Malignant cervical lymphadenopathy: diagnostic accuacy of diffusion – weighted MR Imaging. Radiology 2007, 245: 806–813. 10.1148/radiol.2451061804PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.